Indian Journal of Critical Care Case Report

Register      Login

VOLUME 3 , ISSUE 2 ( March-April, 2024 ) > List of Articles

CASE REPORT

Secondary Hemophagocytic Lymphohistiocytosis Associated with Coronavirus Disease 2019

Smita Sharma, Gyanendra Agrawal, Esha Kaul, Diksha D Yadav

Keywords : Coronavirus disease 2019, Hemophagocytic lymphohistiocytosis, Macrophage activation syndrome

Citation Information : Sharma S, Agrawal G, Kaul E, Yadav DD. Secondary Hemophagocytic Lymphohistiocytosis Associated with Coronavirus Disease 2019. 2024; 3 (2):46-48.

DOI: 10.5005/jp-journals-11006-0100

License: CC BY-NC 4.0

Published Online: 15-03-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Hemophagocytic lymphohistiocytosis (HLH) is an acute and rapidly progressive systemic inflammatory disorder characterized by cytopenia, hyperferritinemia, multiorgan involvement, and hemophagocytosis. The other names for HLH are hemophagocytic syndrome and macrophage activation syndrome. Coronavirus disease 2019 (COVID-19) is associated with cytokine storm and secondary HLH; both are a spectrum of dysregulated immune responses requiring immunomodulatory drugs. Early diagnosis and treatment are a must, as the mortality rate of HLH is 40%. Severe COVID-19 patients should be screened for hyperinflammation using standard laboratory tests and H-score to rule out secondary HLH. Highlight: This case report highlights the importance of a high index of suspicion of secondary HLH in clinician's minds, which can lead to early diagnosis, prompt treatment, and a good prognosis.


PDF Share
  1. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet 2014;383(9927):1503–1516. DOI: 10.1016/S0140-6736(13)61048-X
  2. Carvelli J, Piperoglou C, Farnarier CC, et al. Functional and genetic testing in adults with HLH do not reveal a cytotoxicity defect but rather an inflammatory profile. Blood 2020;136(5):542–552. DOI: 10.1182/blood.2019003664
  3. Rivellese F, Prediletto E. ACE2 at the Centre of COVID-19 from pauci symptomatic infections to severe pneumonia. Autoimmun Rev 2020;19(6):102536. DOI: 10.1016/j.autrev.2020.102536
  4. Knaak C, Nyvlt P, Schuster FS, et al. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care 2020;24(1):244. DOI: 10.1186/s13054-020-02941-3
  5. Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50(6):1227–1235. DOI: 10.1002/pbc.21423
  6. Lin TF, Ferlic-Stark LL, Allen CE, et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011;56(1):154–155. DOI: 10.1002/pbc.22774
  7. Hayden A, Lin M, Park S, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv 2017;1(26):2529–2534. DOI: 10.1182/bloodadvances.2017012310
  8. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66(9):2613–2620. DOI: 10.1002/art.38690
  9. Opoka-Winiarska V, Grywalska E, Roliński J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?. BMC Med 2020;18(1):214. DOI: 10.1186/s12916-020-01682-y
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.